{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T19:27:34Z","timestamp":1786562854648,"version":"build-2736575974"},"reference-count":10,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To report a case of progressive ischemic retinopathy and optic neuropathy in a patient with heavy chain deposition disease (HCDD), a rare form of monoclonal immunoglobulin deposition disease (MIDD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Observations:<\/jats:title>\n                    <jats:p>Our case describes a 74-year-old woman diagnosed with IgG1 lambda HCDD. After treatment with daratumumab and intravenous IVIG therapy, the patient developed worsening ischemic retinopathy and optic neuropathy, neovascular glaucoma, and bilateral sequential vitreous hemorrhages, necessitating surgical intervention. We present multimodal imaging from the onset of ischemic retinopathy to end-stage maculopathy illustrated by optical coherence tomography (OCT) angiography. Despite discontinuing treatment with daratumumab and providing maximal ocular interventions to control the complications of neovascular disease, the patient's condition progressed, resulting in profound vision loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Importance:<\/jats:title>\n                    <jats:p>Our case illustrates the potential for HCDD to cause end-organ disease, including ischemic retinopathy and optic neuropathy, possibly worsened by the patient's underlying cardiovascular risk factor status and medications. Daratumumab, a humanized IgG1 kappa monoclonal antibody that binds to CD38 used to treat specific blood cancers, has been reported to cause disturbances in retinal blood flow, including retinal artery and vein occlusions. It remains to be determined whether careful patient selection or dose adjustments and timing of HCDD treatments could protect vision by reducing the risk of these rare yet severe ocular complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11206721241257553","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T20:09:16Z","timestamp":1717099756000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Bilateral sequential ischemic retinopathy and optic neuropathy in IgG1 heavy chain deposition disease"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2025-7500","authenticated-orcid":false,"given":"Matthew J.","family":"Finn","sequence":"first","affiliation":[{"name":"Lahey Department of Surgery, Division of Ophthalmology, UMass Chan Medical School, University of Massachusetts, Burlington, MA, USA"},{"name":"Tufts University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Sharma","sequence":"additional","affiliation":[{"name":"Lahey Department of Surgery, Division of Ophthalmology, UMass Chan Medical School, University of Massachusetts, Burlington, MA, USA"},{"name":"Tufts University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Guenena","sequence":"additional","affiliation":[{"name":"Spindel Eye Associates, Derry, NH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[{"name":"Lahey Department of Surgery, Division of Ophthalmology, UMass Chan Medical School, University of Massachusetts, Burlington, MA, USA"},{"name":"Tufts University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shravan V.","family":"Savant","sequence":"additional","affiliation":[{"name":"Lahey Department of Surgery, Division of Ophthalmology, UMass Chan Medical School, University of Massachusetts, Burlington, MA, USA"},{"name":"Tufts University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Lahey Department of Surgery, Division of Ophthalmology, UMass Chan Medical School, University of Massachusetts, Burlington, MA, USA"},{"name":"Tufts University School of Medicine"},{"name":"Spindel Eye Associates, Derry, NH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-013-0812-x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.JNMS.2019_86-1"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302851"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000351"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/112067219500500202"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-199004000-00005"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.73.7.552"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.80.12.1083"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.05.029"},{"key":"e_1_3_3_11_2","unstructured":"U.S. Food and Drug Administration. Center for Drug Evaluation and Research. FDA Adverse Event Reporting System (FAERS) public dashboard https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard (2021 accessed 14 October 2022 and 29 January 2023)."}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721241257553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721241257553","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721241257553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T18:32:49Z","timestamp":1786559569000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721241257553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1177\/11206721241257553"],"URL":"https:\/\/doi.org\/10.1177\/11206721241257553","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}